APO Research
Talk to an analyst

APO RESEARCH · REPORT

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchLeber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market include Alkeus Pharmaceuticals, Biovista, Editas Medicine, GenSight Biologics, Ixchel Pharma, Khondrion, Mitotech, ProQR Therapeutics and Spark Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market size, projected growth trends, production technologies, key applications, and end-use industries.

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Company

Alkeus Pharmaceuticals

Biovista

Editas Medicine

GenSight Biologics

Ixchel Pharma

Khondrion

Mitotech

ProQR Therapeutics

Spark Therapeutics

Stealth BioTherapeutics

Usher Syndrome

Amgen

Sanofi

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Type

Dominant Optic Atrophy

Recessive Optic Atrophy

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Application

Hospitals

Medical Research Institute

Eye Clinics

Other

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) significant trends, drivers, influence factors in global and regions.

6. To analyze Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) industry.

Chapter 3: Detailed analysis of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends Table 2. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Drivers Table 3. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Opportunities and Challenges Table 4. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Restraints Table 5. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Company (2021-2026) Table 7. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Company (2021-2026) Table 9. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Company Manufacturing Base & Headquarters Table 12. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company, Product Type & Application Table 13. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dominant Optic Atrophy Table 18. Significant Companies of Recessive Optic Atrophy Table 19. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2021-2026) & (k pcs) Table 21. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2027-2032) & (k pcs) Table 22. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Type (2021-2026) Table 23. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Type (2027-2032) Table 24. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type (2021-2026) Table 28. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Medical Research Institute Table 31. Significant Companies of Eye Clinics Table 32. Significant Companies of Other Table 33. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 34. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2021-2026) & (k pcs) Table 35. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2027-2032) & (k pcs) Table 36. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Application (2021-2026) Table 37. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Application (2027-2032) Table 38. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application (2021-2026) Table 42. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application (2027-2032) Table 43. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 44. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2021-2026) & (k pcs) Table 45. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Region (2021-2026) Table 46. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2027-2032) & (k pcs) Table 47. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Region (2027-2032) Table 48. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Region (2021-2026) Table 51. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Region (2027-2032) Table 53. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Average Price (US$/pcs) by Region (2021-2026) Table 54. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Average Price (US$/pcs) by Region (2027-2032) Table 55. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 56. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026) & (k pcs) Table 58. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2021-2026) Table 59. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032) & (k pcs) Table 60. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2027-2032) Table 61. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Market Share by Country (2021-2026) Table 63. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Market Share by Country (2027-2032) Table 65. Alkeus Pharmaceuticals Company Information Table 66. Alkeus Pharmaceuticals Business Overview Table 67. Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 68. Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 69. Alkeus Pharmaceuticals Recent Development Table 70. Biovista Company Information Table 71. Biovista Business Overview Table 72. Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 73. Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 74. Biovista Recent Development Table 75. Editas Medicine Company Information Table 76. Editas Medicine Business Overview Table 77. Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 78. Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 79. Editas Medicine Recent Development Table 80. GenSight Biologics Company Information Table 81. GenSight Biologics Business Overview Table 82. GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 83. GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 84. GenSight Biologics Recent Development Table 85. Ixchel Pharma Company Information Table 86. Ixchel Pharma Business Overview Table 87. Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 88. Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 89. Ixchel Pharma Recent Development Table 90. Khondrion Company Information Table 91. Khondrion Business Overview Table 92. Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 93. Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 94. Khondrion Recent Development Table 95. Mitotech Company Information Table 96. Mitotech Business Overview Table 97. Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 98. Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 99. Mitotech Recent Development Table 100. ProQR Therapeutics Company Information Table 101. ProQR Therapeutics Business Overview Table 102. ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 103. ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 104. ProQR Therapeutics Recent Development Table 105. Spark Therapeutics Company Information Table 106. Spark Therapeutics Business Overview Table 107. Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 108. Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 109. Spark Therapeutics Recent Development Table 110. Stealth BioTherapeutics Company Information Table 111. Stealth BioTherapeutics Business Overview Table 112. Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 113. Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 114. Stealth BioTherapeutics Recent Development Table 115. Usher Syndrome Company Information Table 116. Usher Syndrome Business Overview Table 117. Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 118. Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 119. Usher Syndrome Recent Development Table 120. Amgen Company Information Table 121. Amgen Business Overview Table 122. Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 123. Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 124. Amgen Recent Development Table 125. Sanofi Company Information Table 126. Sanofi Business Overview Table 127. Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 128. Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 129. Sanofi Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors List Table 133. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Image Figure 2. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (2021-2032) & (k pcs) Figure 5. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dominant Optic Atrophy Image Figure 10. Recessive Optic Atrophy Image Figure 11. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Type (2021-2032) Figure 14. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Medical Research Institute Image Figure 19. Eye Clinics Image Figure 20. Other Image Figure 21. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 22. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Application (2021-2032) Figure 24. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application (2021-2032) Figure 27. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 28. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Dominant Optic Atrophy
  • Recessive Optic Atrophy
Applications
  • Hospitals
  • Medical Research Institute
  • Eye Clinics
  • Other
Companies covered
  • Alkeus Pharmaceuticals
  • Biovista
  • Editas Medicine
  • GenSight Biologics
  • Ixchel Pharma
  • Khondrion
  • Mitotech
  • ProQR Therapeutics
  • Spark Therapeutics
  • Stealth BioTherapeutics
  • Usher Syndrome
  • Amgen
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  4. 1.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume (2021-2032)
  5. 1.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Dynamics
  1. 2.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends
  2. 2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Drivers
  3. 2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Opportunities and Challenges
  4. 2.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Restraints
3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Company
  1. 3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Revenue Ranking in 2025
  2. 3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Company (2021-2026)
  3. 3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Company (2021-2026)
  4. 3.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Price by Company (2021-2026)
  5. 3.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Ranking (2024-2026)
  6. 3.6 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Manufacturing Base and Headquarters
  7. 3.7 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Product Type and Application
  8. 3.8 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Type
  1. 4.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Type Introduction
  2. 4.1.1 Dominant Optic Atrophy
  3. 4.1.2 Recessive Optic Atrophy
  4. 4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type
  5. 4.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type
  9. 4.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type (2021-2032)
5 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Application
  1. 5.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Medical Research Institute
  4. 5.1.3 Eye Clinics
  5. 5.1.4 Other
  6. 5.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application
  7. 5.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application
  11. 5.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application (2021-2032)
6 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Regional Sales and Value Analysis
  1. 6.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2021-2032)
  3. 6.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021-2026
  4. 6.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2027-2032)
  5. 6.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Region (2027-2032)
  9. 6.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  12. 6.6.2 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  15. 6.7.2 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  21. 6.9.2 South America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Country, 2025 VS 2032
7 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Country-level Sales and Value Analysis
  1. 7.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2032)
  4. 7.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026)
  5. 7.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032)
  6. 7.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alkeus Pharmaceuticals
  2. 8.1.1 Alkeus Pharmaceuticals Company Information
  3. 8.1.2 Alkeus Pharmaceuticals Business Overview
  4. 8.1.3 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  6. 8.1.5 Alkeus Pharmaceuticals Recent Developments
  7. 8.2 Biovista
  8. 8.2.1 Biovista Company Information
  9. 8.2.2 Biovista Business Overview
  10. 8.2.3 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  12. 8.2.5 Biovista Recent Developments
  13. 8.3 Editas Medicine
  14. 8.3.1 Editas Medicine Company Information
  15. 8.3.2 Editas Medicine Business Overview
  16. 8.3.3 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  18. 8.3.5 Editas Medicine Recent Developments
  19. 8.4 GenSight Biologics
  20. 8.4.1 GenSight Biologics Company Information
  21. 8.4.2 GenSight Biologics Business Overview
  22. 8.4.3 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  24. 8.4.5 GenSight Biologics Recent Developments
  25. 8.5 Ixchel Pharma
  26. 8.5.1 Ixchel Pharma Company Information
  27. 8.5.2 Ixchel Pharma Business Overview
  28. 8.5.3 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  30. 8.5.5 Ixchel Pharma Recent Developments
  31. 8.6 Khondrion
  32. 8.6.1 Khondrion Company Information
  33. 8.6.2 Khondrion Business Overview
  34. 8.6.3 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  36. 8.6.5 Khondrion Recent Developments
  37. 8.7 Mitotech
  38. 8.7.1 Mitotech Company Information
  39. 8.7.2 Mitotech Business Overview
  40. 8.7.3 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  42. 8.7.5 Mitotech Recent Developments
  43. 8.8 ProQR Therapeutics
  44. 8.8.1 ProQR Therapeutics Company Information
  45. 8.8.2 ProQR Therapeutics Business Overview
  46. 8.8.3 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  48. 8.8.5 ProQR Therapeutics Recent Developments
  49. 8.9 Spark Therapeutics
  50. 8.9.1 Spark Therapeutics Company Information
  51. 8.9.2 Spark Therapeutics Business Overview
  52. 8.9.3 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  54. 8.9.5 Spark Therapeutics Recent Developments
  55. 8.10 Stealth BioTherapeutics
  56. 8.10.1 Stealth BioTherapeutics Company Information
  57. 8.10.2 Stealth BioTherapeutics Business Overview
  58. 8.10.3 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  60. 8.10.5 Stealth BioTherapeutics Recent Developments
  61. 8.11 Usher Syndrome
  62. 8.11.1 Usher Syndrome Company Information
  63. 8.11.2 Usher Syndrome Business Overview
  64. 8.11.3 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  66. 8.11.5 Usher Syndrome Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Value Chain Analysis
  2. 9.1.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Mode & Process
  6. 9.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors
  9. 9.2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst